Agreement - June 7, 2017
Veloxis Pharmaceuticals in a new agreements
The company’s US subsidiary, Veloxis Pharmaceuticals, Inc., has entered into an exclusive license, supply and distribution agreement with Taiba Healthcare to register, commercialize and distribute Envarsus XR in certain countries throughout the Middle East and North Africa (MENA) region. Under the terms of the agreement, Veloxis will receive an up-front payment and a one-time sales […]
Clinical Trials - May 5, 2015
Transplant Drug Shows Promise
Veloxis Pharmaceuticals’ once-daily Envarsus® XR (tacrolimus extended-release tablets), an investigational new drug under FDA review for the prevention of organ rejection in adult kidney transplant patients, demonstrated that a lower, once-a-day dose of Envarsus XR in African-American kidney transplant patients is sufficient to achieve therapeutic tacrolimus blood concentrations, compared to twice-daily immediate release tacrolimus. The […]
